Leadership

Parth Khanna, Co-Founder & CEO
Kapil Kalra, Co-Founder & CCO
Kumar Erramilli, Co-Founder & CTO

Sector
Healthcare Technology

ACTO is an AI-powered SaaS platform purpose-built to support brand performance in the life science industry by preparing field professionals for face-to-face interactions with healthcare professionals (HCPs). ACTO enables field teams to become “Masters of the Message” by enhancing their training, practice, certification, coaching, and message recall, while equipping commercial leaders with real-time insights into field performance and impact, enabling smarter, data-driven decisions.

2024

September


$10M Equity Financing

2024

June

Acquired 4th Down Solutions

2022

July


Questa Led $18M Series B Financing

ACTO

“The life sciences industry is actively looking for new ways to leverage AI to bring drugs to market faster but no one is focused on the ‘human touch’ element. We are excited to supercharge our AI development to eliminate this gap and bring fresh innovation to the market.”

Parth Khanna

CEO

Their story

Today, the responsibility of pharma reps and medical science liaisons to educate HCPs on treatment options – to improve patient outcomes – is at an all-time high. Yet, with dwindling access to HCPs, field teams must capitalize on face-to-face meetings, maximizing the relevance and impact of each interaction.

In 2014, former University of Waterloo roommates Parth Khanna, Kapil Kalra, and Kumar Erramilli came together with a shared vision: to improve how pharma, biotech, and med device companies engage with HCPs. They founded ACTO to equip field professionals with the tools needed to deliver impactful, compliant messaging with confidence and authority. By consolidating multiple training and enablement solutions into a single platform, ACTO provides seamless, on-demand access to resources, materials and compliance tools. Today, ACTO enables over 30,000 field professionals in life sciences.

Our partnership

We met ACTO two years before our initial investment, allowing us to develop a strong rapport with its three founders. We were impressed by the strength of the management team and the blue-chip customer base they had built.

We saw a clear opportunity to support a unified and AI-driven platform in a market long dominated by fragmented point solutions. ACTO is well positioned to tackle some of the most pressing challenges in the life sciences industry, and its innovative approach to enhancing human interaction between sales teams and physicians sets it apart.

“We believe ACTO’s early focus and deep expertise in AI, along with their demonstrated success in solving challenges faced by pharma companies, positions them to best lead the AI charge on the commercial side of life sciences.”

Ryan Drant, Founder & Managing Partner

Questa Capital